The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

First Xarelto Trial Underway in Philadelphia Mass Tort Program

Posted on November 10, 2017 by Larry Bodine

XareltoA trial over the blood thinner Xarelto, made by Janssen Pharmaceuticals Inc. and Bayer Pharma AG, is underway in the Philadelphia Court of Common Pleas, where more than 1,500 Xarelto bleeding claims have been centralized in a mass tort program.

Lynn Hartman of Indiana charges she suffered serious gastrointestinal bleeding after using the novel anticoagulant for a little over a year.  (Case No. 160503416)

During the opening statements, the plaintiff attorney Gary Douglas of Douglas & London asserted that the drug’s manufacturers manipulated clinical trial data and downplayed important safety information to make Xarelto appear safer and more effective than competing blood thinners, such as warfarin.

“Our firm is representing a number of plaintiffs who are pursuing similar Xarelto claims. We will be watching the Philadelphia trial closely for any developments that could impact our clients’ cases,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP.

Xarelto Bleeding Allegations

Approved by the U.S. Food & Drug Administration in October 2011, Xarelto is jointly marketed by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals subsidiary. The blood thinner is currently indicated for the prevention of strokes in people with atrial fibrillation; the treatment of patients suffering from deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in people undergoing hip or knee implant surgery.

Like other new-generation blood thinners, Xarelto has been touted as an improvement over decades-old warfarin. However, internal bleeding caused by warfarin can be stopped by the administration of vitamin K. There is currently no approved agent to reverse Xarelto bleeding.

Johnson & Johnson’s most recent earnings statement indicates that more than 21,000 Xarelto lawsuits have been filed in courts throughout the United States.

Plaintiffs involved in this litigation claim that the drug’s manufacturers downplayed the potential for Xarelto bleeding and wrongly promoted the drug as a superior alternative to warfarin. In addition to noting the lack of a reversal agent for Xarelto bleeding, plaintiffs take issue with the medication’s one-size-fits-all dosing regimen and dispute the defendants’ assertions that there is no need to subject Xarelto patients to routine blood monitoring.

The majority of Xarelto lawsuits are currently pending in a federal multidistrict litigation underway in the U.S. District Court, Eastern District of Louisiana, where three trials have already concluded with defense verdicts. There are 18,526 lawsuits pending before US District Judge Eldon E. Fallon in MDL 2592, IN RE: Xarelto (Rivaroxaban) Products Liability Litigation. Additional Xarelto bleeding claims have been filed in Delaware, California and Missouri state courts.

Xarelto patients who allegedly experienced bleeding-related complications may be entitled to compensation for their medical bills, lost wages, pain and suffering, and more.

Posted in Blog, Mass Torts, Product Liability

Comments are closed.

News Categories

Read about other Top Jury Verdicts

Total Settlement in Surfside Condo Collapse Tops $1 Billion

Total Settlement in Surfside Condo Collapse Tops $1 Billion

The proposed settlement reached nearly a year after the catastrophic Surfside building collapse along the South Flo[Read More...]
UCLA Will Pay Nearly $700 Million in Abuse Lawsuits

UCLA Will Pay Nearly $700 Million in Abuse Lawsuits

The University of California system announced Tuesday it will pay nearly $375 million to more than 300 women who said they we[Read More...]
Things to Consider When You Sue an Insurance Provider

Things to Consider When You Sue an Insurance Provider

We are all too acquainted with insurance coverage in our everyday lives. According to Investopedia, everyone should have[Read More...]
The Rochester Diocese Offers a $147 Million Settlement to Sex Abuse Survivors

The Rochester Diocese Offers a $147 Million Settlement to Sex Abuse Survivors

The Rochester Catholic Diocese is offering a $147 million settlement to sex abuse survivors. This offer comes as a federal ba[Read More...]
Jury Awards $77.5 Million to an Army Veteran in a 3M Earplug Case

Jury Awards $77.5 Million to an Army Veteran in a 3M Earplug Case

A jury in Pensacola, Fla., federal court on Friday ordered 3M to pay $77.5 million to a U.S. Army veteran who said he suffe[Read More...]

#LegalNews

@@TheNTLtop100

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.